Live Breaking News & Updates on Destiny Breast09 Trial

Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research. ....

United States , Dana Farber Cancer Institute , Andrew Mckenzie , Howarda Burris , Paolo Tarantino , Ian Krop , Denise Yardley , Sarah Cannon Research Institute , Science Summit , Breast Cancer , Gynecologic Cancer Research , Patients With Her2 Positive Breast Cancer , Erikap Hamilton , Trastuzumab Deruxtecan , Patritumab Deruxtecan , Destiny Breast09 Trial , Natalee Trial , Adjuvant Ribociclib Plus An Aromatase Inhibitor , Patients With Hr Positive , Er2 Negative Early Breast Cancer , Sacituzumab Govitecan , Molecular Profiling In Tnbc , Testing For Her2 In Patients With Breast Cancer ,